ABCL Latest Headlines

AbCellera Tees Up New Phase 1/2 ABCL635 Data at TMS, Spotlighting a Long-Acting Non-Hormonal Approach to Hot Flashes

Market Chameleon (Fri, 9-Oct 7:55 AM)

AbCellera sets November 9 date for Q3 2026 results and a 3:00 p.m. Pacific earnings call

Market Chameleon (Fri, 2-Oct 9:04 AM)

AbCellera Sets October 2026 Spotlight for ABCL635 Phase 2 Menopause Symptom Data

Market Chameleon (Thu, 17-Sep 7:10 AM)

AI Drug Discovery Advances: AbCellera’s Integrated Platform Draws Investor Focus as Industry Shifts to Function-Based Models

Market Chameleon (Wed, 19-Aug 9:16 AM)

AbCellera’s Strong Phase 2 Data Spotlight New Highs and Next Steps for ABCL635

Market Chameleon (Wed, 12-Aug 7:07 AM)

ABCL Phase 2 Results Spark Renewed Interest: 83% Reduction in Vasomotor Symptoms Stands Out

Market Chameleon (Tue, 11-Aug 11:21 AM)

ABCL635 Delivers Statistically Significant Phase 2 Results—50% Greater Reduction in Hot Flashes Over Placebo

Market Chameleon (Mon, 10-Aug 10:31 AM)

ABCL635’s Phase 2 Results Show 83% Mean Reduction in Hot Flashes—A Potential Shift for Menopausal Symptom Relief

Market Chameleon (Mon, 10-Aug 7:06 AM)

AbCellera Bolsters Liquidity With $100M in New Collaborations Despite Higher Q2 2026 Losses

Market Chameleon (Thu, 6-Aug 7:18 AM)

AbCellera Secures $28 Million Vertex Deal to Advance T-Cell Engager Platform for Autoimmune Therapies

Market Chameleon (Wed, 29-Jul 7:37 AM)